No Data
No Data
Press Release: BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, t
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma with a Overweight and maintains $70 price target.
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
J.P. Morgan analyst Anupam Rama maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 5.0% over the
Buy Rating Affirmed for BridgeBio Pharma Amid Market Overreaction and Promising Long-Term Prospects